Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core

• US 5,800,829 A
• Filed: 05/24/1995
• Issued: 09/01/1998
• Est. Priority Date: 04/25/1991
• Status: Expired due to Term

• Current Assignee: Neurotech S.A. (LivaNova Plc)
• Original Assignee: Brown University
• Inventors: Emerich, Dwaine F., Aebischer, Patrick, Sanberg, Paul R., Dionne, Keith E., Lysaght, Michael J., Vasconcellos, Alfred V., Gentile, Frank T., Christenson, Lisa, Scharp, David W., Hegre, Orion D., Hoffman, Diane, Lacy, Paul E.
• Primary Examiner(s): Bawa, Raj
• Application Number:
  US08/449,274
• Time in Patent Office: 1,196 Days
• Field of Search: 424/422, 424/423, 424/424, 424/426, 424/427, 424/430, 424/434, 424/437, 424/489, 424/490
• US Class Current: 424/422
• CPC Class Codes: A61K 2035/126 Immunoprotecting barriers, e.g. jackets, diffusion chambers
• CPC Class Codes: A61K 2035/128 capsules, e.g. microcapsules
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0092 Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
• CPC Class Codes: C12N 2510/00 Genetically modified cells

Abstract

A method of making an immunoisolatory vehicle comprised of a core comprising living cells dispersed in a biocompatible matrix is disclosed, the cells being capable of secreting a biologically active product or of providing a metabolic or immunologic function to an individual, and an external jacket surrounding said core which is a biocompatible, permselective thermoplastic or hydrogel, said jacket being free of said cells, comprising coextruding a suspension comprising said cells dispersed in a precursor matrix material comprising extracellular matrix components or a biocompatible hydrogel precursor, and a solution of a biocompatible jacket precursor from a nested dual-bore extrusion nozzle, wherein the suspension of (a) is coextruded from the inner bore and the solution of (b) is coextruded from the outer bore of the nozzle, to form said jacket as the solution of (b) and the suspension of (a) arc coextruded; and exposing the vehicle to a treatment that forms a core comprising a volume of at least 1 μl and at least 10⁴ cells and comprising a biocompatible matrix from the precursor matrix of solution (a).

Claims

1. A method of making an immunoisolatory vehicle comprised of a core comprising living cells dispersed in a biocompatible hydrogel matrix, said cells being capable of secreting a biologically active product or of providing a metabolic or immunologic function to an individual, and an external jacket surrounding said core which is a biocompatible, permselective thermoplastic or hydrogel, said jacket being free of said cells, comprising coextruding:

(a) a suspension comprising said cells dispersed in a biocompalible hydrogel matrix precursor, and

(b) a solution of a biocompatible jacket precursor from a nested dual-bore extrusion nozzle, wherein the suspension of (a) is coextruded from the inner bore and the solution of (b) is coextruded from the outer bore of the nozzle, to form said jacket as the solution of (b) and the suspension of (a) are coextruded; and

(c) exposing the vehicle to a treatment that forms a core comprising a hydrogel matrix from the hydrogel matrix precursor of solution (a) and comprising a volume of at least 1 μ

l and at least 10⁴ cells.

2. The method of claim 1, wherein the biocompatible hydrogel matrix precursor of (a) comprises an alkali metal alginate which is coextruded with the solution of (b) into an aqueous multivalent cation-containing solution.

3. The method of claim 1, wherein the solution of (b) comprises a hydrogel matrix precursor, and the cell suspension of (a) and the solution of (b) are coextruded to form a jacket comprising a hydrogel matrix from the hydrogel matrix precursor of solution (b).

4. The method of any one of claims 1, 2 or 3, wherein the solution of (b) comprises an alkali metal alginate, and the cell suspension of (a) and the solution of (b) are coextruded into an aqueous calcium chloride solution.

5. The method of claim 1 or 2, wherein the solution of (b) comprises a water-insoluble thermoplastic polymer or copolymer dissolved in a water-miscible solvent and the suspension of (a) and the solution of (b) are coextruded into an aqueous liquid.

11. The method of any one of claims 1, 2, 6 or 7 wherein the jacket is selected from the group consisting of polyacrylonitnile-polyviniylchloride, polyacrylonitrile, polymethylmethacrylate, polyvinyldifluorido, polyolefins, polysulfones and celluloses.

12. The method of claim 1, 2, 6 or 7 wherein the jacket further comprises a hydrophilic or hydrophobic additive.

13. The method of claims 1 or 6 wherein the the biocompatible matrix core is selected from the group consisting of alginate, collagen, laminin-containing hydrogels, agarose, cellulose, methylcellulose, block copolymer of ethylene-vinylalcohol, sodium polystyrene sulfonate, vinyl-methyl-tribenzyl ammonium chloride, phosphazene, and polyvinylalcohol.

14. The method of claim 1 wherein the biocompatible matrix core is selected from the group consisting of collagen, laminin, glycoaminoglycans, proteoglycans, fibronectin, elastin, and mixtures thereof.

15. The method of claim 14 wherein the glycosaminoglycans are selected from the group consisting of hyaluronic acid, chondroitin sulfate, heparin, and heparin sulfate.

16. The method of claim 1 or 6 wherein the biologically active product is selected from the group consisting of antibodies, enzymes, trophic factors, growth factors, hormones, biological response modifiers, cytokines, lymphokine and neurotransmitters.

17. The method of claim 1 or 6 wherein the biologically active product is selected from the group consisting of enkephalins, catecholamines, opioid peptides, and mixtures thereof.

18. The method of claim 1 or 6 wherein the suspension of (a) further comprises accessory cells.

19. The method of claim 1 or 6 wherein the cells are primary cells.

20. The method of claim 1 or 6 wherein the cells are selected from the group consisting of insulin-producing cells, adrenal chromaffin cells, antibody-secreting cells, fibroblasts, astrocytes, Beta cell lines, and Chinese hamster ovary cells.

21. The method of claim 1 or 6 wherein the cells are neural stem cells.

22. The method of claim 1 or 6 wherein the cells are adrenal chromaffin cells.

23. The method of claim 1 or claim 6 wherein the core has a volume in excess of 10 μ

l.

24. The method of claim 1 or 6 wherein the jacket is between 5 and 200 μ

m thick.

25. The method of claim 1 or 6 wherein the jacket has a molecular weight cutoff between 50 kD and 2000 kD.

26. The method of claim 1 or 6 wherein the jacket is shaped to form a hollow fiber.

27. The method of claim 1 or 6 wherein the jacket is shaped to form a flat sheet.

6. A method of making an immunoisolatory vehicle comprised of a core comprising living cells dispersed in a biocompatible matrix, said cells being capable of secreting a biologically active product or of providing a metabolic or immunologic function to an individual, and an external jacket surrounding said core which is a biocompatible, permselective thermoplastic or hydrogel, said jacket being free of said cells, comprising coextruding:

(a) a suspension comprising said cells dispersed in a precursor matrix comprising extracellular matrix components or a biocompatible hydrogel precursor, and

(b) a solution of a biocompatible jacket precursor from a nested dual-bore extrusion nozzle, wherein the suspension of (a) is coextruded from the inner bore and the solution of (b) is coextruded from the outer bore of the nozzle, to form said jacket as the solution of (b) and the suspension of (a) are coextruded; and

(c) exposing the vehicle to a treatment that forms a core comprising a biocompatible matrix from the precursor matrix of solution (a) and comprising a volume of at least 1 μ

l and at least 10⁴ cells.

7. The method of claim 6, wherein the biocompatible precursor matrix of (a) comprises an alkali metal alginate which is coextruded with the solution of (b) into an aqueous multivalent cation-containing solution.

8. The method of claim 6, wherein the solution of (b) comprises a hydrogel matrix precursor, and the cell suspension of (a) and the solution of (b) are coextruded to form a jacket comprising a hydrogel matrix from the hydrogel matrix precursor of solution (b).

9. The method of any one of claims 6-8, wherein the solution of (b) comprises an alkali metal alginate, and the cell suspension of (a) and the solution of (b) are coextruded into an aqueous calcium chloride solution.

10. The method of claim 6 or 7, wherein the solution of (b) comprises a water-insoluble thermoplastic polymer or copolymer dissolved in a water-miscible solvent and the suspension of (a) and the solution of (b) are coextruded into an aqueous liquid.